Antibodies against Epstein-Barr virus gp78 antigen: A novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology

Journal of General Virology

Volumn 89, Issue 5, 2008, Pages 1152-1158

  Gu, Ai Di ^a   Xie, Yan Bo ^a   Mo, Hao Yuan ^a   Jia, Wei Hua ^a   Li, Miao Yan ^b   Li, Ming ^b   Chen, Li Zhen ^a   Feng, Qi Sheng ^a   Liu, Quentin ^a   Qian, Chao Nan ^a   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GLYCOPROTEIN GP78; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; VIRUS CAPSID ANTIGEN; VIRUS GLYCOPROTEIN; BIOLOGICAL MARKER; MATRIX PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; AGED; BLOOD; CARCINOMA; EVALUATION; IMMUNOLOGY; MIDDLE AGED; NASOPHARYNX TUMOR;

HUMAN HERPESVIRUS 4; MIRIDAE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOLOGICAL MARKERS; CARCINOMA; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; VIRAL MATRIX PROTEINS;

EID: 44649117639     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83686-0     Document Type: Article

References (48)

1. Amon, W. & Farrell, P. J. (2005). Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15, 149-156.
2. Biagini, R. E., Sammons, D. L., Smith, J. P., MacKenzie, B. A., Striley, C. A., Robertson, S. A., Snawder, J. E. & Quinn, C. P. (2005). Simultaneous measurement of specific serum IgG responses to five select agents. Anal Bioanal Chem 382, 1027-1034.
3. Busson, P., Keryer, C., Ooka, T. & Corbey, M. (2004). EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12, 356-360.
4. Chen, R., Lowe, L., Wilson, J. D., Crowther, E., Tzeggai, K., Bishop, J. E. & Varro, R. (1999). Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 45, 1693-1694.
5. Cohen, J. I. (2000). Fpstein-Barr virus infection. N Fngl J Med 343, 481-492.
6. Dardari, R., Hinderer, W., Lang, D., Benider, A., El Gueddari, B., Joab, I., Benslimane, A. & Khyatti, M. (2001). Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 39, 3164-3170.
7. Deng, H., Zeng, Y., Lei, Y., Zhao, Z., Wang, P., Li, B., Pi, Z., Tan, B., Zheng, Y. & other authors (1995). Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J (Engl) 108, 300-303.
8. Dolyniuk, M., Wolff, E. & Kieff, E. (1976). Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol 18, 289-297.
9. Dunbar, S. A., Vander Zee, C. A., Oliver, K. G., Karem, K. L. & Jacobson, J. W. (2003). Quantitative, multiplexed detection of bacterial pathogens: DNA and protein apphcations of the Luminex LabMAP system. J Microbiol Methods 53, 245-252.
10. Earley, M. C., Vogt, R. F., Jr, Shapiro, H. M., Mandy, F. F., Kellar, K. L., Bellisario, R., Pass, K. A., Marti, G. E., Stewart, C. C. & Hannon, W. H. (2002). Report from a workshop on multianalyte microsphere assays. Cytometry 50, 239-242.
11. Elshal, M. F. &. McCoy, J. P. (2006). Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38, 317-323.
12. Epstein, M. A., Henle, G., Achong, B. G. & Barr, Y. M. (1965). Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma. J Exp Med 121, 761-770.
13. Fachiroh, J., Schouten, T., Hariwiyanto, B., Paramita, D. K., Harijadi, A., Haryana, S. M., Ng, M. H. & Middeldorp, J. M. (2004). Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190, 53-62.
14. Fachiroh, J., Paramita, D. K., Hariwiyanto, B., Harijadi, A., Dahlia, H. L., Indrasari, S. R., Kusumo, H., Zeng, Y. S., Schouten, T. & other authors (2006). Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 44, 1459-1467.
15. Farrel, P. J. (2005). Epstein-Barr virus genome. In Epstein-Barr virus, pp. 263-287. Edited by E. S. Robertson. Norwich, UK: Caister Academic Press.
16. Feng, P., Chan, S. H., Soo, M. Y., Liu, D., Guan, M., Ren, E. C. & Hu, H. (2001). Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis. Cancer 92, 1872-1880.
17. Fones-Tan, A., Chan, S. H., Tsao, S. Y., Gan, L. H., Tan, W. H., Li, B., Khong, P. W. & Gan, Y. Y. (1994). Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma. Int J Cancer 59, 739-742.
18. Foong, Y. T., Cheng, H. M., Sam, C. K., Dillner, J., Hinderer, W. & Prasad, U. (1990). Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 45, 1061-1064.
19. Fulton, R. J., McDade, R. L., Smith, P. L., Kienker, L. J. & Kettman, J. R., Jr (1997). Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 43, 1749-1756.
20. Gastpar, H., Wilmes, E. & Wolf, H. (1981). Epidemiologic, etiologic and immunologic aspects of nasopharyngeal carcinoma (NPC). J Med 12, 257-284.
21. Gong, M., Ooka, T., Matsuo, T. & Kieff, E. (1987). Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol 61, 499-508.
22. Gulley, M. L. (2001). Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 3, 1-10.
23. Hadar, T., Rahima, M., Kahan, E., Sidi, J., Rakowsky, E., Sarov, B. & Sarov, I. (1986). Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. J Med Virol 20, 329-339.
24. Heineman, T., Gong, M., Sample, J. & Kieff, E. (1988). Identification of the Epstein-Barr virus gp85 gene. J Virol 62, 1101-1107.
25. Henle, G. & Henle, W. (1976). Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17, 1-7.
26. Ho, S., Teo, P., Kwan, W. H., Choi, P., Tiong, J. & Johnson, P. J. (1998). Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Oral Oncol 34, 491-495.
27. Johannsen, E., Luftig, M., Chase, M. R., Weicksel, S., Cahir-McFarland, E., Illanes, D., Sarracino, D. & Kieff, E. (2004). Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101, 16286-16291.
28. Kettman, J. R., Davies, T., Chandler, D., Oliver, K. G. & Fulton, R. J. (1998). Classification and properties of 64 multiplexed microsphere sets. Cytometry 33, 234-243.
29. Khanna, R., Burrows, S. R. & Moss, D. J. (1995). Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 59, 387-405.
30. Khanna, R., Moss, D. J. & Burrows, S. R. (1999). Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cefl-mediated immune regulation. Immunol Rev 170, 49-64.
31. Klutts, J. S., Liao, R. S., Dunne, W. M., Jr & Gronowski, A. M. (2004). Evaluation of a multiplexed bead assay for assessment of Epstein-Barr virus immunologic status. J Clin Microbiol 42, 4996-5000.
32. Leung, S. F., Tam, J. S., Chan, A. T., Zee, B., Chan, L. Y., Huang, D. P., Van Hasselt, A., Johnson, P. J. & Lo, Y. M. (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 50, 339-345.
33. Littler, E., Baylis, S. A., Zeng, Y., Conway, M. J., Mackett, M. & Arrand, J. R. (1991). Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337, 685-689.
34. Lukacs, Z., Dietrich, A., Ganschow, R., Kohlschutter, A. & Kruithof, R. (2005). Simultaneous determination of HIV antibodies, hepatitis C antibodies, and hepatitis B antigens in dried blood spots - a feasibility study using a multi-analyte immunoassay. Clin Chem Lab Med 43, 141-145.
35. Mackett, M., Conway, M. J., Arrand, J. R., Haddad, R. S. & Hutt-Fletcher, L. M. (1990). Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHl I fragment. J Virol 64, 2545-2552.
36. North, J. R., Morgan, A. J., Thompson, J. L. & Epstein, M. A. (1982). Purified Epstein-Barr virus Mr 340,000 glycoprotein induces Potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A 79, 7504-7508.
37. Old, L. J., Boyse, E. A., Oettgen, H. F., Harven, E. D., Geering, G., Williamson, B. & Clifford, P. (1966). Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 56, 1699-1704.
38. Pattie, S. B. & Farrell, P. J. (2006). The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 6, 1193-1205.
39. Pickard, A., Chen, C. J., Diehl, S. R., Liu, M. Y., Cheng, Y. J., Hsu, W. L., Sun, B., Hsu, M. M., Chen, I. H. & other authors (2004). Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 111, 117-123.
40. Raab-Traub, N. (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12, 431-441.
41. Raab-Traub, N., Flynn, K., Klein, C., Pizza, G., De Vinci, C., Occhiuzzi, L., Farneti, G., Caliceti, U. & Pirodda, E. (1987). EBV associated malignancies. J Exp Pathol 3, 449-456.
42. Skogstrand, K., Thorsen, P., Norgaard-Pedersen, B., Schendel, D. E., Sorensen, L. C. & Hougaard, D. M. (2005). Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood Spots by immunoassay with xMAP technology. Clin Chem 51, 1854-1866.
43. Szakonyi, G., Klein, M. G., Hannan, J. P., Young, K. A., Ma, R. Z., Asokan, R., Holers, V. M. & Chen, X. S. (2006). Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13, 996-1001.
44. Tao, Q., Young, L. S., Woodman, C. B. & Murray, P. G. (2006). Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 11, 2672-2713.
45. Tarbouriech, N., Buisson, M., Geoui, T., Daenke, S., CusacK, S. & Burmeister, W. P. (2006). Structural genomics of the Epstein-Barr virus. Acta Crystallogr D Biol Crystallogr 62, 1276-1285.
46. Urquiza, M., Lopez, R., Patino, H., Rosas, J. E. & Patarroyo, M. E. (2005). Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells. J Biol Chem 280, 35599-35605.
47. Xu, J., Ahmad, A., Blagdon, M., D'Addario, M., Jones, J. F., Dolcetti, R., Vaccher, E., Prasad, U. & Menezes, J. (1998). The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int J Cancer 79, 481-486.
48. Yip, T. T. Ngan, R. K., Lau, W. H., Poon, Y. F., Joab, I., Cochet, C. & Cheng, A. K. (1994). A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74, 2414-2424.